Posted on May 20, 2020 by Sitemaster
Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 1 Comment »
Posted on April 27, 2020 by Sitemaster
According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … overall survival (OS)” in men with metastatic, castration-resistant prostate cancer (mCRPC) and BRCA1/2 or ATM gene mutations (homologous repair gene mutations or HRRm). … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: gene, Lynparza, mCRPC, mutation, olaparib, Profound, repair | 11 Comments »
Posted on October 1, 2019 by Sitemaster
From a report presented by Hussain yesterday at the annual meeting of the European Society for Medical Oncology (ESMO) we gained detailed insight into the results of the PROfound trial of olaparib (Lynparza), which had been said to be positive last August. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, gene, Lynparza, mCRPC, metastatic, mutation, olaparib | 3 Comments »
Posted on August 7, 2019 by Sitemaster
According to a media release issued jointly yesterday by AstraZeneca and Merck, treatment with the PARP inhibitor olaparib (Lynparza) has demonstrated “positive results from the Phase III PROfound trial … in [a subset of] men with metastatic castration-resistant prostate cancer (mCRPC).” … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ATM, BRCA1/2, castration-resistant, mCRPC, metastatic, olaparib, PARP | 2 Comments »
Posted on March 29, 2019 by Sitemaster
Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, castration-resistant, first line, inhibitor, mCRPC, metastatic, olaparib, PARP | 4 Comments »
Posted on March 1, 2019 by Sitemaster
Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Uncategorized | Tagged: inhibitor, mCRPC, niraparib, olaparib, PARP, Phase III, rucaparib, talazoparib | 5 Comments »
Posted on October 28, 2015 by Sitemaster
A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 3 Comments »
Posted on April 21, 2015 by Sitemaster
According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: inhibitor, Lynparza, olaparib, PARP | 4 Comments »
Posted on December 20, 2014 by Sitemaster
On Friday this week the U.S. Food and Drug Administration approved a drug known as olaparib (Lynparza®) for the treatment of a very specific form of very late stage ovarian cancer. This may be of interest to some men with late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: BRCA mutation, olaparib | Leave a comment »
Posted on November 5, 2014 by Sitemaster
According to a report on the Reuters web site yesterday, some researchers are of the opinion that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (recently recommended for approval in Europe for the treatment of a subset of women with ovarian cancer) may be valuable in the treatment of some forms of prostate cancer too. … READ MORE …
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, inhibitor, mCRPC, metastatic, olaparib, PARP | 2 Comments »
Posted on May 16, 2013 by Sitemaster
Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, BRCA1, BRCA2, olaparib | 2 Comments »
Posted on June 25, 2009 by Sitemaster
A report in this week’s issue of the New England Journal of Medicine (which is never shy about promoting itself) provides more early, and interesting, evidence of the future potential of so-called PARP inhibitors in cancer therapy. … READ MORE …
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: MSI-201, olaparib, PAP inhibitor | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 